Original researchComparison of abortions induced by methotrexate or mifepristone followed by misoprostol☆
Section snippets
Materials and methods
This was a multicenter, randomized, nonblinded, controlled trial comparing medical abortions induced by mifepristone followed by misoprostol with those induced by methotrexate followed by misoprostol with respect to completed abortion without need for surgery as demonstrated by endovaginal scan. Other outcome measures included the percentage of abortions completed by day 8, complications, side effects, and patient acceptability. This study was approved by the Clinical Research Ethics Board of
Results
There were 1411 women screened for this study; 1146 were found eligible and 80 declined, resulting in 1066 being randomized. Twenty-four women dropped out after randomization but before treatment leaving 1042 who received medications. There were 518 women in the methotrexate group and 524 in the mifepristone group. There were no significant differences in the two groups with respect to maternal age, gestational age, ethnicity, or obstetric history (Table 1).
Three women were lost to follow-up.
Discussion
The most important difference between the two drug regimens was the speed of action. The bleeding started sooner after the misoprostol in the mifepristone group (3.0 hours) compared with the methotrexate group (4.6 hours). The actual day of abortion was earlier (mean 3.3 days compared with 7.1 days, median 3 days compared with 5 days). This is expected as the misoprostol was administered more quickly after the mifepristone than the methotrexate (at least 36 hours compared with at least 96
References (38)
- et al.
Acceptability of medical abortion with methotrexate and misoprostol
Contraception
(1995) - et al.
Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486
Contraception
(1989) - et al.
Progesterone receptor blockage. Effect on uterine contractility and early pregnancy
Contraception
(1985) - et al.
Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone
Lancet
(1991) - et al.
Methotrexate and misoprostol for early abortion
Contraception
(1993) Choosing between surgical abortions and medical abortions induced with methotrexate and misoprostol
Contraception
(1997)Abortion induced with methotrexate and misoprostolA comparison of various protocols
Contraception
(1997)Methotrexate and misoprostol for abortion at 57–63 days’ gestation
Contraception
(1994)- et al.
Oral methotrexate and vaginal misoprostol for early abortion
Contraception
(1998) - et al.
A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion
Contraception
(1999)
Conceptual age and ultrasound measurements of gestational sac and crown-rump length in vitro fertilization pregnancies
Fertil Steril
Pain control in abortion
Int J Gynecol Obstet
The measurement of clinical pain intensityA comparison of six methods
Pain
Low dose mifepristone 200 mg and vaginal misoprostol for abortion
Contraception
Further acceptability evaluation of RU486 and ONO 802 as abortifacient agents in a Chinese population
Contraception
Conditions for choosing between drug-induced and surgical abortions
Contraception
Safety, efficacy, and acceptability of medical abortion in China, Cuba, and IndiaA comparative trial of mifepristone-misoprostol versus surgical abortion
Am J Obstet Gynecol
Randomized controlled trial of fentanyl for abortion pain
Am J Obstet Gynecol
Medical methods for termination of pregnancy
Cited by (45)
Medication abortion with misoprostol-only: A sample protocol
2023, ContraceptionToxicity of abortifacients: A review for physicians in the post roe era
2022, American Journal of Emergency MedicineCitation Excerpt :While methotrexate has been used in the past in medication abortion regimens, its use has been largely supplanted by mifepristone and misoprostol regimens, which have a much better toxicity profile and higher efficacy rates. Methotrexate regimens have similar efficacy to misoprostol alone, as methotrexate has limited activity as an abortifacient-it simply creates a non-viable gestion [26]. A common regimen is 50 mg/m2 intramuscular methotrexate followed by 800 μg of misoprostol vaginally 72 h later.
Medical induced abortion
2016, Journal de Gynecologie Obstetrique et Biologie de la ReproductionMedications Used in Evidence-Based Regimens for Medical Abortion: An Overview
2016, Journal of Obstetrics and Gynaecology CanadaCitation Excerpt :This combined effect may explain the short duration of the MA process and rapid onset of expulsion of the pregnancy after MISO administration in MIFE/MISO regimens. As shown in a Canadian RCT,5 abortions induced with use of MIFE/MISO were completed faster than those induced with use of MTX/MISO, although the overall success rates at 36 days after induction were similar. By the eighth day after the first medication (MIFE or MTX), 90.5% of women in the MIFE group (n = 474) had aborted completely compared with 74.5% of women in the MTX group (n = 386); the mean number of days from beginning to completion was 3.3 days for MIFE and 7.1 days for MTX (P < 0.001).5
Medical Abortion
2016, Journal of Obstetrics and Gynaecology CanadaCitation Excerpt :One major difference between these MTX/MISO and MIFE/MISO regimens is the longer delay to obtain complete abortion. A Canadian randomized, controlled trial of 1042 women demonstrated completion by day 8 in 75.5% in the MTX/MISO group compared with 90.5% in the MIFE/MISO group, and the mean number of days to completion was 7.1 days and 3.3 days, respectively.142 In a large multicenter trial, 69.7%, 87.7%, and 91.7% using MTX/MISO completed their abortion by 14, 28, and 35 days, respectively.
Comparison of remote and in-clinic follow-up after methotrexate/misoprostol abortion
2015, ContraceptionCitation Excerpt :Where mifepristone is unavailable, as in Canada, methotrexate with misoprostol is an alternative. Although shown to be as effective as mifepristone for abortions up to 49 days gestation, the process with methotrexate is longer and less predictable [1,2]. Methotrexate is highly teratogenic [3], raising concerns about the need for follow-up to ensure pregnancy termination.
- ☆
This study was funded by the Province of British Columbia.
We gratefully acknowledge the assistance of Drs. Ludek Podhradsky, Inna Tcherenkova, and Jonathan Berkowitz.